Reveal: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: Local innate immune activation and systemic adaptive immune expansion for treating solid tumors Meeting Abstract
| Authors: | Diab, A.; Curti, B.; Bilen, M.; Brohl, A.; Domingo-Musibay, E.; Borazanci, E.; Fanton, C.; Haglund, C.; Vimal, M.; Muhsin, M.; Marcondes, M.; Nguyen, A.; Tagliaferri, M.; Lin, W.; Zalevsky, J.; D'Angelo, S. |
| Abstract Title: | Reveal: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: Local innate immune activation and systemic adaptive immune expansion for treating solid tumors |
| Meeting Title: | 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 8 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2020 Nov 9-14 |
| Meeting Location: | Virtual |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2020-11-01 |
| Start Page: | A224 |
| End Page: | A225 |
| Language: | English |
| ACCESSION: | WOS:000616665300357 |
| DOI: | 10.1136/jitc-2020-SITC2020.0368 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 368 -- Source: Wos |
